Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREAS SCHMID

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1962663377
CMS profile
761022
Location
KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$72.62

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $72.62 4

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Insmed, Inc. $72.62 4

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREAS SCHMID

NPI 1962663377 · CMS profile ID 761022

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962663377?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962663377?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962663377?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ANDREAS SCHMID, NPI 1962663377, CMS profile ID 761022, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1962663377?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $72.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Insmed, Inc. $13.5810/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186284500 CMS
Insmed, Inc. $21.0608/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186320120 CMS
Insmed, Inc. $16.9306/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186285394 CMS
Insmed, Inc. $21.0502/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186324842 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,930.13 21
PY2020 $7,244.44 9
PY2023 $1,117.56 9
PY2024 $15.37 1
PY2025 $72.62 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,654.12 9
PY2025 Principal investigator $330,468.44 168
PY2024 Principal investigator $383,470.04 191
PY2023 Principal investigator $688,078.36 235
PY2022 Principal investigator $419,549.56 143
PY2021 Principal investigator $95,534.58 57
PY2019 Principal investigator $7,217.27 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Insmed, Inc. $2,279.84 12/14/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866695
Principal investigator 1 Insmed, Inc. $177.22 12/14/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866703
Principal investigator 1 Insmed, Inc. $144.18 12/14/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866705
Principal investigator 1 Insmed, Inc. $157.40 12/14/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866707
Principal investigator 1 Insmed, Inc. $3,210.01 12/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866689
Principal investigator 1 Insmed, Inc. $600.00 12/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866697
Principal investigator 1 Insmed, Inc. $600.00 12/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866699
Principal investigator 1 Insmed, Inc. $2,553.19 12/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866701
Principal investigator 1 Insmed, Inc. $1,547.71 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782177
Principal investigator 1 Insmed, Inc. $1,547.71 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782183
Principal investigator 1 Insmed, Inc. $1,547.71 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782187
Principal investigator 1 Insmed, Inc. $1,547.71 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782189
Principal investigator 1 Insmed, Inc. $1,547.71 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782191
Principal investigator 1 Insmed, Inc. $1,547.71 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782195
Principal investigator 1 Insmed, Inc. $1,547.71 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782199
Principal investigator 1 Insmed, Inc. $1,547.71 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782201
Principal investigator 1 Insmed, Inc. $1,547.71 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782205
Principal investigator 1 Insmed, Inc. $1,547.71 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782207
Principal investigator 1 Insmed, Inc. $0.46 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782213
Principal investigator 1 Insmed, Inc. $1.27 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782215
Principal investigator 1 Insmed, Inc. $1.27 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782217
Principal investigator 1 Insmed, Inc. $1.41 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782221
Principal investigator 1 Insmed, Inc. $1.41 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782223
Principal investigator 1 Insmed, Inc. $1.41 11/04/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782225
Principal investigator 1 Insmed, Inc. $850.00 10/28/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866685
Principal investigator 1 Insmed, Inc. $848.00 10/28/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866687
Principal investigator 1 Insmed, Inc. $2,110.44 10/28/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866691
Principal investigator 1 Insmed, Inc. $1,875.01 10/28/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866693
Principal investigator 1 Insmed, Inc. $1,547.71 10/07/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782179
Principal investigator 1 Insmed, Inc. $1,547.71 10/07/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782181
Principal investigator 1 Insmed, Inc. $1,547.71 10/07/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782185
Principal investigator 1 Insmed, Inc. $1,547.71 10/07/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782193
Principal investigator 1 Insmed, Inc. $1,547.71 10/07/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782197
Principal investigator 1 Insmed, Inc. $1,547.71 10/07/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782203
Principal investigator 1 Insmed, Inc. $1.27 10/07/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782209
Principal investigator 1 Insmed, Inc. $0.46 10/07/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782211
Principal investigator 1 Insmed, Inc. $1.41 10/07/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782219
Principal investigator 1 Insmed, Inc. $1.41 10/07/2021 Non-covered Recipient Entity
University of Kansas Medical Center
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 942782227
Principal investigator 1 Insmed, Inc. $1,459.00 09/30/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866737
Principal investigator 1 Insmed, Inc. $11,250.00 09/30/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866739
Principal investigator 1 Insmed, Inc. $1,750.00 09/30/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866741
Principal investigator 1 Insmed, Inc. $527.33 09/30/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866743
Principal investigator 1 Insmed, Inc. $2,063.57 08/26/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866735
Principal investigator 1 Insmed, Inc. $3,750.00 08/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866711
Principal investigator 1 Insmed, Inc. $6,700.00 08/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866713
Principal investigator 1 Insmed, Inc. $1,750.00 08/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866715
Principal investigator 1 Insmed, Inc. $800.00 08/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866717
Principal investigator 1 Insmed, Inc. $1,459.00 08/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866719
Principal investigator 1 Insmed, Inc. $6,700.00 08/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866725
Principal investigator 1 Insmed, Inc. $3,750.00 08/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866727
Principal investigator 1 Insmed, Inc. $800.00 08/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866729
Principal investigator 1 Insmed, Inc. $1,459.00 08/06/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) No dispute reported 06/30/2026 849866731
Principal investigator 1 Insmed, Inc. $3,210.01 07/29/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866721
Principal investigator 1 Insmed, Inc. $2,553.19 07/29/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866723
Principal investigator 1 Insmed, Inc. $1,820.27 07/29/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866733
Principal investigator 1 Insmed, Inc. $3,500.00 06/24/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849866709
Principal investigator 1 Insmed, Inc. $52.78 06/14/2021 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 849863747